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Abstract 
Background: Neuropathic pain is characterized by hyperalgesia, allodynia and spontaneous 
pain. It often occurs as a result of injury to peripheral nerves, dorsal root ganglions (DRG), 
spinal cord, or brain. Recent studies have suggested that Toll-like receptor 4 (TLR4) might 
play a role in neuropathic pain. Methodology/Principal Findings: In this study, we inves-
tigated the role of TLR4 in a rat chronic constriction injury (CCI) model and explored the 
feasibility of treating neuropathic pain by inhibiting TLR4. Our results demonstrated that in-
trathecal siRNA-mediated suppression of TLR4 attenuated CCI-induced mechanical allodynia 
and thermal hyperalgesia through inhibiting the activation of NF-κB p65 and production of 
proinflammatory cytokines (e.g., TNF-α and IL-1β).  Conclusions/Significance: These 
findings suggest that suppression of TLR4 mediated by intrathecally administered siRNA may 
be a new strategy for the treatment of neuropathic pain. 
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Introduction 
Neuropathic pain is characterized by hyperalge-
sia, allodynia and spontaneous pain. It often occurs as 
a result of injury to peripheral nerves, dorsal root 
ganglions (DRG), spinal cord, or brain. 7% to 8% of 
the population suffer from neuropathic pain, and 5% 
may be severely affected (1-2). Neuropathic pain re-
mains a prevalent and persistent clinical challenge 
due to unknown pathogenesis. A variety of mechan-
isms have been proposed for the induction and/or 
maintenance of neuropathic pain. Recently, investi-
gations have focused on the role of central nervous 
system (CNS) immune responses after nerve injuries 
that lead to behavioral hypersensitivity (3-5). A cur-
rent theory for the etiology of neuropathic pain in-
volves CNS immune activation with cytokine pro-
duction inducing the expression of final common pain 
mediators such as TNF-α and IL-1β (6-8). 
The Toll-like receptor 4 (TLR4) has recently been 
implicated in chronic neuropathic pain (9-10). TLR4 is 
a transmembrane receptor protein containing extra-
cellular domains with leucine-rich repeat and a cy-
toplasmic signaling domain. The role of TLR4 in in-
nate immune response has been well elucidated. The 
binding of exogenous (e.g. Lipopolysaccharides, LPS) 
or endogenous (e.g. members of heat shock protein 
family and proteoglycans) ligands to TLR4 activates Int. J. Med. Sci. 2010, 7 
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NF-κB and then releases proinflammatory cytokines 
such as TNF-α, IL-1β and IL-6 (11-13). Previous stu-
dies have demonstrated that TLR4 is expressed in 
microglia of CNS (14-16). Since microglial activation is 
essential for the release of proinflammatory cytokines 
(17), it is plausible that TLR4 might be a common 
mediator through which different pain-inducing sig-
nals are linked to the production of proinflammatory 
factors. Consistent with this notion, 
N-methyl-D-aspartate (NMDA) receptor-modulated 
innate immune responses were dependent on TLR4 
(18), and mice with TLR4 deficiency demonstrated 
decreased cytokine production and attenuated neu-
ropathic pain responses upon nerve injury (19). 
In this study, we suppressed TLR4 expression 
using siRNA in a rat CCI model. Knockdown of TLR4 
in spinal cord inhibited pain response, and blocked 
NF-κB activation and production of proinflammatory 
cytokines (e.g. IL-1β and TNF-α). 
Materials and methods 
Ethics Statement 
All animal experiments were approved by the 
Administrative Committee of Experimental Animal 
Care and Use of Second Military Medical University 
(SYXK(Hu)2007-0003), and conformed to the National 
Institute of Health guidelines on the ethical use of 
animals. 
Screening siRNA sequence with reporter vector 
A scrambled sequence was designed as a mis-
match control (MM-siRNA) (5’-GGCGUGUCUCUCU 
UACGAC-3”). SiRNAs targeting the cDNA sequence 
of rat TLR4 (GenBank accession NM_019178) were: 
5’-CUACCAACAGAGAGGAUAU-3” (siRNA1), 
5’-GUCUCAGAUAUCUAGAUCU-3’ (siRNA2), 
5’-GAGCCGGAAAGUUAUUGUG-3’ (siRNA3).  
All siRNAs were chemically synthesized by 
United Gene Company (Shanghai, China). The pri-
mers amplifying the full length cDNA of rat TLR4 
were 5'-CGGGAGCTCTGAATGCTCTCTTGCATC 
TGGCTGGC-3’ (forward) and 5'-CGGGTCGACGCG 
ATACAATTCGACCTGCTG-3’ (reverse). 
To construct a green fluorescent protein (GFP) 
tagged TLR4 expressing vector, total RNA was ex-
tracted from rat lung tissues using Tri-Reagent (Ta-
KaRa, Japan). RT-PCR was used to obtain the full 
length TLR4 fragment. After pEGFPC1 vector was 
linearized by SacⅠ and SalⅠ, the fragment of TLR4 
was inserted to construct the reporter vector, 
pEGFPC1-TLR4. The reporter vector was verified by 
RT-PCR using primers 5'-CGGGAGCTCTGAA 
TGCTCTCTTGCATCTGGCTGGC-3’ and 5'-CGGGT 
CGACGCGATACAATTCGACCTGCTG-3’.  
To construct a green fluorescent protein (GFP) 
tagged TLR4 expressing vector, total RNA was ex-
tracted from rat lung tissues using Tri-Reagent (Ta-
KaRa, Japan). RT-PCR was used to obtain the full 
length TLR4 fragment. After pEGFPC1 vector was 
linearized by SacⅠ and SalⅠ, the fragment of TLR4 
was inserted to construct the reporter vector, 
pEGFPC1-TLR4. The reporter vector was verified by 
RT-PCR using primers 5'-CGGGAGCTCTGAA 
TGCTCTCTTGCATCTGGCTGGC-3’ and 5'-CGGGT 
CGACGCGATACAATTCGACCTGCTG-3’.  
To identify the knockdown efficacy of different 
siRNA oligonucleotides, HEK-293 cells were cotrans-
fected with pEGFPC1-TLR4 and siRNA (iRNA1-3, 
respectively) with lipofectamine2000 (Invitrogen, 
USA). EGFP expression was observed under an in-
verted fluorescence microscope and the fluorescence 
intensity was quantified by flow cytometry. 
To identify the knockdown efficacy of different 
siRNA oligonucleotides, HEK-293 cells were cotrans-
fected with pEGFPC1-TLR4 and siRNA (iRNA1-3, 
respectively) using lipofectamine2000 (Invitrogen, 
USA). An oligonucleotide sequence with no homolo-
gy to the sequence of TLR4 was used as a mismatch 
controls. After 48 h, cells were visualized under an 
inverted fluorescence microscope and the inhibitory 
effects of different siRNA oligonucleotides were de-
termined by measuring EGFP expression using flow 
cytometry. 
Animals and chronic constriction injury 
Male Sprague-Dawley rats (200-250g) were 
purchased from Shanghai Experimental Animal Cen-
ter, Chinese Academy of Sciences. The chronic con-
striction injury (CCI) model was established as pre-
viously described (20). Briefly, rats were anesthetized 
with sodium pentobarbital (40 mg/kg, i.p.). The 
common sciatic nerve was exposed at the mid-thigh 
level. The nerve was ligated loosely with 4-0 chromic 
gut thread at 4 sites with an interval of 1 mm, so that 
the nerve diameter was only slightly reduced. 
Meanwhile, a sham surgery was performed with the 
sciatic nerve exposed but not ligated. Upon recovery 
from anesthesia, animals were housed individually in 
clear plastic cages with the floor covered by 3-6 cm of 
sawdust.  
Lumbar subarachnoid catheterization 
One week prior to CCI, a chronic indwelling 
catheter was implanted into the subarachnoid space 
of each rat. Briefly, rats were anesthetized with so-
dium pentobarbital (40 mg/kg, i.p.). A PE-10 catheter 
(Becton Dickinson, Sparks, MD, USA) was inserted 
into the lumbar subarachnoid space between 5th and Int. J. Med. Sci. 2010, 7 
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6th lumbar vertebrae (L5) and L6 (21). The catheter 
was chronically implanted and the external portion of 
the catheter was protected according to Milligan’s 
method (22).  
Intrathecal delivery of siRNA  
Rats were randomly divided into four groups 
with 10 rats in each group: a sham group (Sham sur-
gery + Normal saline, NS), a CCI group (CCI + NS), a 
MM group (CCI + MM siRNA), and a siRNA group 
(CCI + TLR4-siRNA). 10 μg SiRNA dissolved in 30 μl 
i-Fect transfection reagent (Neuromics, Edina, MN, 
USA) was administered intrathecally once daily for 7 
days, starting from 1 day before CCI surgery. 
Evaluation of tactile allodynia and thermal 
hyperalgesia 
The paw withdrawal latency (PWL) to radiant 
heat and paw withdrawal threshold (PWT) were used 
to evaluate thermal hyperalgesia and mechanical al-
lodynia respectively as previously described (23-24). 
T o  m e a s u r e  P W L ,  r a t s  w e r e  p l a c e d  i n  a n  i n v e r t e d  
clear plexiglass cage (23×18×13 cm) on a piece of 
3-mm-thick glass plate and allowed to acclimate to 
their surroundings for 30 minutes before testing. After 
acclimation, the radiant heat source was positioned 
under the glass floor directly beneath the hind paw. 
The radiant heat source consisted of a high-intensity 
projection lamp bulb (8V, 50W), located 40 mm below 
the glass floor and projecting through a 5×10-mm 
aperture in the top of a movable case. A digital timer 
automatically recorded the duration between the start 
of stimuli and the paw withdrawal (PWL). Three trials 
were carried out in each rat with a 5-minute interval. 
The cut-off was set at 20 seconds to avoid tissue 
damage. 
Mechanical allodynia was assessed with von 
F r e y  f i l a m e n t s .  R a t s  w e r e  p l a c e d  o n  a  w i r e  m e s h  
platform, covered with a transparent plastic dome, 
and allowed to acclimate for 30 minutes before test-
ing. The filament was applied perpendicularly to the 
plantar surface of the hind paw (ipsilateral to the side 
of CCI). The paw withdrawal threshold (PWT) was 
determined by sequentially increasing and decreasing 
the stimulus intensity (the ‘up-and-down’ method) (in 
gram, g), and data were analyzed using the nonpa-
rametric method of Dixon (24). Tests were performed 
1 day before CCI surgery, and 1, 3, 7, 10 and 14 days 
after CCI surgery. 
Enzyme linked immunosorbent assay (ELISA) 
Dorsal spinal cord tissue and cerebrospinal fluid 
(CSF) samples were prepared as previously described 
(25). IL-1β and TNF-α in spinal cord tissues and CSF 
were detected by ELISA (Peprotech, UK).  
Spinal cord RNA extraction and real time PCR 
Total RNA was extracted from L4–L5 spinal cord 
tissues. Extracted RNA was pretreated with DNaseⅠ 
at 37Ԩ for 30 minutes before reverse transcription 
reaction was performed using a high capacity cDNA 
archived kit (TaKaRa, Japan). A Real-Time PCR De-
tection System (Roche, Switzerland) was used to con-
tinuously monitor the intensity of fluorescence, which 
was directly proportional to the PCR products. 
Western blotting 
Nuclear extracts were prepared from lumbar 
spinal cord (L4-L5) tissues as previously described 
(26). Proteins were separated on an 8% polyacryla-
mide SDS-PAGE gel and transferred onto a nitrocel-
lulose membrane. The nitrocellulose membrane was 
blotted with a primary antibody recognizing the p65 
subunit of NF-κB (1:100, Santa Cruz, CA, USA), fol-
lowed by a secondary antibody conjugated with 
horseradish peroxidase. Protein signals were detected 
with an ECL system (Amersham Pharmacia Biotech, 
Uppsala, Sweden). Histone3 (Sigma, St. Louis, MO, 
USA, 1:500) was used as an internal control.  
Statistical analyses 
Data are expressed as mean ± standard deviation 
(SD). Statistical analyses were performed using Stu-
dent's t-test or multiple ANOVA followed by 
least-significance difference post-hoc comparison. 
P<0.05 was considered statistically significant. 
 
Results 
Identification of pGEFPC1-TLR4 
The TLR4 fragment of 2376 bp was successfully 
obtained by PT-PCR. Restriction analysis and se-
quencing results demonstrated that the recombinant 
pEGFP-TLR4 indeed contained the TLR4 fragment. 
Silencing of TLR4 transgene with siRNA in 
HEK-293 cells 
In order to select a siRNA oligonucleotide for an 
efficient knockdown of TLR4, three siRNA oligonuc-
leotides targeting the rat TLR4 were used to cotrans-
fect pEGFPC1-TLR4 in HEK-293 cells in vitro and then 
the level of TLR4 transgene expression was evaluated 
by GFP fluorescence (Figure 1A). Meanwhile, the rel-
ative fluorescence intensity was also detected by flow 
cytometry (Figure 1B). Flow cytometry and fluoresce 
observation revealed that all 3 siRNAs demonstrated 
effective inhibition on GFP fluorescence, and 
TLR4-siRNA2 was the most potent. Therefore, 
TLR4-siRNA2 was used for further in vivo study.  Int. J. Med. Sci. 2010, 7 
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Figure 1. Screening siRNA for an efficient suppression of TLR4 expression in vitro. HEK-293 cells were co-transfected with 
both pEGFRC1-TLR4 and either one of three independent siRNA oligonucleotides targeting TLR4 (TLR4-siRNA1-3) or a 
control siRNA (MM-siRNA). Two days after transfection, EGFP fluorescence was observed under microscope (A) or 
quantified by flow cytometry (B). (A) EGFP fluorescence under an inverted fluorescence microscope (×100) or cell density 
under an optical microscope (×100). A, control; B, siRNA1; C, siRNA2; D, siRNA3. (B) The quantification of TLR4-EGFP 
fluorescence intensity upon siRNA knockdown was evaluated by flow cytometry analysis. Immunofluorescence and flow 
cytometry results revealed that all 3 siRNAs had efficient inhibition on GFP fluorescence, and TLR4-siRNA2 was the most 
potent. 
 
 
Effects of TLR4-siRNA on TLR4 and its down-
stream signaling in CCI rats  
Real time RT-PCR showed a significant 
up-regulation of TLR4 mRNA expression 1 day after 
C C I  c o m p a r e d  t o  t h e  s h a m  g r o u p  ( P = 0 . 0 0 0 0 ) .  T h e  
siRNA-TLR4 decreased TLR4 mRNA expression and 
continued for 7 days (P=0.0003). However, there was 
no significant difference in TLR4 mRNA expression 
between 10-14 days after CCI (Figure 2A, 2B). The 
TLR4 protein expression in spinal cord tissues was 
detected by Western blotting. No statistical difference 
was found between CCI group and MM siRNA group 
for nuclear TLR4 protein expression (P=0.6062). Inte-
restingly, activation of NF-κB p65 was also blocked by 
the TLR4-siRNA treatment (P=0.0070) (Figure 2C). 
Thus, the TLR4 mRNA and protein in spinal cord 
tissues were decreased by siRNA-TLR4, and inhibi-
tory effects of siRNA on TLR4 expression were con-
firmed at the mRNA and protein levels. 
TNF-α and IL-1β were up-regulated in the dorsal 
spinal cord tissues of CCI rats, and there were no sig-
nificant differences in TNF-α and IL-1β between the Int. J. Med. Sci. 2010, 7 
 
http://www.medsci.org 
255
CCI group and MM group (P>0.05). However, com-
pared with the MM group, the production of TNF-α 
and IL-1β in spinal cord tissues was significantly 
lower in the CCI group during the course of 
TLR4-siRNA treatment, indicating that intrathecal 
administration of TLR4-siRNA significantly atte-
nuated TLR4 induction in the CCI rats (Figure 3).  
 
 
 
Figure 2. Inhibition of TLR4 signaling upon TLR4-siRNA in CCI rats. Either saline or 10μg of selected siRNA was admi-
nistered intrathecally once daily for 7 days as described in Materials and Methods. Tissue biopsy was performed from lumbar 
L4-L5 spinal cord tissues at indicated time points as described. A RT-PCR analyses of TLR4 mRNA expression in rat lumbar 
spinal cord tissues in four groups one day after CCI. Maker, DL200; Lane 1, CCI group; Lane 2, MM group; Lane 3, siR-
NA-TLR4 group; Lane 4, sham group. B Real-time quantitative RT-PCR analyses of TLR4 mRNA expression in rat lumbar 
spinal cord tissues in four groups (* P<0.05 VS MM group), sham group (Sham surgery + NS), CCI group (CCI + NS), MM 
group (CCI + MM siRNA), siRNA group (CCI + TLR4-siRNA). C Western blotting showed the levels of NF-κB P65 protein 
in spinal cord of rat tissues in four groups. Interestingly, the expression of κB p65 protein in the TLR4-siRNA treatment 
group was significantly lower than the MM group (P=0.0070). Int. J. Med. Sci. 2010, 7 
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Figure 3 CCI-induced pro-inflammatory cytokines in lumbosacral spinal cord tissues were inhibited upon TLR4-siRNA 
administration. Student t-test was performed and IL-1 (A) and TNF-α (B) production in the spinal cord tissues in the siRNA 
group was significantly lower compared with the MM group (* P<0.05 VS MM group). Sham group (Sham surgery + NS), CCI 
group (CCI + NS), MM group (CCI + MM siRNA), siRNA group (CCI + TLR4-siRNA). 
 
 
Suppression of TLR4 attenuates neuropathic 
pain in CCI rats  
To examine the impact of TLR4-siRNA treatment 
on pain response in vivo, modulation of pain percep-
tion in the Bennett model of neuropathic pain was 
investigated. PWT and PWL were used to measure 
mechanical allodynia and thermal hyperalgesia, re-
spectively. The PWL and PWT were significantly 
shorter in the CCI rats compared with sham controls. 
Mechanical allodynia and thermal hyperalgesia in-
duced by CCI was attenuated by intrathecal adminis-
tration with TLR4-siRNA (p<0.05, Fig. 4), but not 
mismatched siRNA.  Int. J. Med. Sci. 2010, 7 
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Figure 4 TLR4-siRNA treatment relieved neuropathic pain. Rats were administered with TLR4-siRNA one day before CCI, 
and then pain response was monitored during and after siRNA treatment. Student t-test was performed and significant 
differences were observed on 1, 3, 7d between the siRNA group and MM group (* P<0.05 VS MM group). Mechanical 
allodynia (A) and thermal hyperalgesia (B) was relieved upon TLR4-siRNA treatment in CCI rats. Sham group (Sham surgery 
+ NS), CCI group (CCI + NS), MM group (CCI + MM siRNA), siRNA group (CCI + TLR4-siRNA). 
 
Discussion 
Increasing evidences indicate that TLR4 is im-
plicated in neuropathic pain. In this study, siRNA of 
TLR4 were used to investigate whether blockage of 
TLR4 mRNA could be used for pain treatment and 
whether the downstream factors such as NF-κB or 
proinflammatory factors could be decreased after 
knockdown of TLR4. Our results demonstrated that 
siRNA-mediated suppression of TLR4 attenuated 
CCI-induced mechanical allodynia and thermal 
hyperalgesia. The NF-κB expression and the produc-
tion of TNF-α and IL-1β were inhibited after siR-
NA-TLR4 injection.  
TLR4 antagonists and antisense oligonucleotides 
reduce neuropathic pain in animal models (19, 27). 
However, systemic administration of a TLR4 inhibitor 
may result in non-specific toxicity as well as systemic 
side effects. For example, TLR4 knockout mice are 
prone to infection (28). Local administration of TLR4 
antisense oligonucleotide has demonstrated some 
hypotheses. siRNA is a more promising and advan-
tageous strategy. Several studies have indicated that 
RNAi is more potent than antisense oligonucleotides 
even in cases where site selection was optimized for 
antisense effectiveness (29). One of the potential ad-
vantages of RNAi technologies is the ability to design 
precisely targeted therapeutics for almost any gene, 
regardless of the function of the gene product, 
whether that function is clearly defined, and in the 
absence of protein structure information (30). SiRNA 
targeting P2X3, δ-opioid receptor and NMDA recep-
tor has been explored as potential means to manage 
pain (31-33). RNAi primarily acts within the cytop-
lasmic compartment, which is easier to access using 
nonviral methods than the nucleus, but ensuring effi-
cient uptake and long-term stability in vivo is still 
likely to be difficult (34-35). In this study, the an-Int. J. Med. Sci. 2010, 7 
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ti-nociception effect disappeared after discontinuation 
of siRNA-TLR4, suggesting that vectors or viral me-
thods as lentivirus, adenovirus are needed to achieve 
long-term stable expression of siRNA. 
The activation of TLR4 triggers two major 
downstream signaling cascades, the NF-kB and mi-
togen-activated protein kinase (MAPK) transduction 
cascades (36). The NF-kB cascade leads to release 
pro-inflammatory cytokines (IL-6, IL-1β, TNF-α). The 
MAPK kinases activate extracellular signal-regulated 
kinase (ERK), p38 MAPK, and stress-activated protein 
kinase/c-Jun N-terminal kinase (SAPK/JNK) (37). 
MAPKs are important for intracellular signal trans-
duction and play critical roles in regulating neural 
plasticity and inflammatory responses (38-39). Ac-
cumulating evidence shows that all three MAPK 
pathways contribute to pain sensitization after in-
flammatory and nerve injury via distinct molecular 
and cellular mechanisms (40-42). The present study 
showed that NF-kB and pro-inflammatory cytokines 
(IL-1β, TNF-α) could be down-regulated by siR-
NA-TLR4 in the CCI rats. Whether MAPK kinases are 
down-regulated by siRNA of TLR4 in CCI rats needs 
to be further studied. 
Meanwhile, we also found that the CCI-induced 
mechanical allodynia and thermal hyperalgesia and 
the production of TNF-α and IL-1β were simulta-
neously inhibited after siRNA-TLR4 injection. Sun T 
et al (43) also observed that the changes of mechanical 
and thermal pain thresholds and spinal TNF-α and 
IL-1β mRNA expression were isochronous, and effec-
tive suppression on CCI-induced up-regulation of 
TNF-β mRNA and IL-1α mRNA expression might be 
conducive to reduce mechanical allodynia and ther-
mal hyperalgesia in neuropathic pain rats. These 
findings were coincident with the study of Jancálek R 
and so on (44-46). Thus, we believed that TNF-α and 
IL-1β might mediate the CCI-induced allodynia. But 
the critical experiment of inhibiting NF-kB or TNF-α 
or IL-1β during the CCI to demonstrate there has the 
same effect as TLR4 inhibition on CCI-induced allo-
dynia should be verified in future. 
In summary, results from our study confirmed 
the role of TLR4 pathway in CCI induced neuropathic 
pain. In addition, we have also demonstrated that 
suppression of TLR4 with intrathecal siRNA delivery 
could alleviate pain responses in a rat CCI model, 
suggesting that siRNA targeting TLR4 could be of 
practical value in clinical situation.  
Conflict of Interest 
The authors have declared that no conflict of in-
terest exists. 
References 
1.  Bouhassira D., Lantéri-Minet M., Attal N., Laurent B., Touboul 
C. Prevalence of chronic pain with neuropathic characteristics 
in the general population. Pain. 2008; 136: 380-7. 
2.  Torrance N., Smith B.H., Bennett M.I., Lee A.J. The epidemiol-
ogy of chronic pain of predominantly neuropathic origin. Re-
sults from a general population survey. J Pain. 2006; :7281-9. 
3.  Guo L.H., Schluesener H.J. The innate immunity of the central 
nervous system in chronic pain: the role of Toll-like receptors. 
Cell. Mol. Life. Sci. 2007; 64: 1128-36. 
4.  Zeilhofer H.U. Loss of glycinergic and GABAergic inhibition in 
chronic pain--contributions of inflammation and microglia. Int. 
Immunopharmacol. 2008; 8: 182-7. 
5.  Marchand F., Perretti M., McMahon S.B. Role of the immune 
system in chronic pain. Nat. Rev. Neurosci. 2005; 6: 521-32. 
6.  Sommer C., Galbraith J.A., Heckman H.M., Myers R.R. Pa-
thology of experimental compression neuropathy producing 
hyperesthesia. J. Neuropathol. Exp. Neurol. 1993; 52: 223–33. 
7.  Sorkin L.S., Doom C.M. Epineural application of TNF elicits an 
acute mechanical hyperalgesia in the awake rat. J. Peripheral. 
Nervous. Syst. 2000; 5: 96–100. 
8.  Guneli E., Kazikdas K.C., Kolatan E. Ghrelin may attenuate 
proinflammatory cytokine-mediated neuropathic pain. Med. 
Hypotheses. 2007; 69: 356-60. 
9.  Tanga F.Y., Raghavendra V., DeLeo J.A. Quantitative real-time 
RT- PCR assessment of spinal microglial and astrocytic activa-
tion markers in a rat model of neuropathic pain. Neurochemi-
stry  International. 2004; 45: 397-407. 
10.  Cao L., Tanga F.Y., Deleo J.A. The contributing role of CD14 in 
toll-like receptor 4 dependent neuropathic pain. Neuroscience. 
2009; 158: 896-903. 
11.  Vabulas R.M., Ahmad-Nejad P., Ghose S., Kirschning C.J., Issels 
R.D., Wagner H. HSP70 as endogenous stimulus of the 
Toll/interleukin V 1 receptor signal pathway. J. Biol. Chem. 
2002; 277: 15107-12. 
12. Tsan M.F., Gao B. Cytokine function of heat shock proteins. 
Am. J. Physiol. 2004; 286: C739–C744. 
13.  Kitaoka Y., Munemasa Y., Nakazawa T., Ueno S. 
NMDA-induced interleukin-1beta expression is mediated by 
nuclear factor-kappa B p65 in the retina. Brain. Res. 2007; 1142: 
247-55. 
14. Eklind S., Mallard C., Leverin A.L., Gilland E., Blomgren K., 
Mattsby-Baltzer I., Hagberg H. Bacterial endotoxin sensitizes 
the immature brain to hypoxic-ischaemic injury. Eur. J. Neu-
rosci. 2001; 13: 1101-6. 
15. Lehnardt S., Lachance C., Patrizi S., Lefebvre S., Follett P.L., 
Jensen F.E.,.PRosenberg A., Volpe J.J., Vartanian T. The Toll-like 
receptor TLR4 is necessary for lipopolysaccharide-induced 
oligodendrocyte injury in the CNS. J. Neurosci. 2002; 22: 
2478-86. 
16. Blanco A.M., Guerri C. Ethanol intake enhances inflammatory 
mediators in brain: role of glial cells and TLR4/IL-1RI recep-
tors. Front. Biosci. 2007; 12: 2616-30. 
17.  Detloff M.R., Fisher L.C., McGaughy V., Longbrake E.E., Popo-
vich P.G., Basso D.M. Remote activation of microglia and 
pro-inflammatory cytokines predict the onset and severity of 
below-level neuropathic pain after spinal cord injury in rats. 
Exp. Neurol. 2008; 212: 337-47. 
18. Glezer I., Zekki H., Scavone C., Rivest S. Modulation of the 
innate immune response by NMDA receptors has neuropatho-
logical consequences. J. Neurosci. 2003; 23: 11094-103. 
19.  Tanga F.Y., Nutile-McMenemy N., DeLeo J.A. The CNS role of 
Toll-like receptor 4 in innate neuroimmunity and painful neu-
ropathy. Proc. Natl. Acad.Sci. 2005; 19102: 5856-61. Int. J. Med. Sci. 2010, 7 
 
http://www.medsci.org 
259
20.  Bennett G.J., Xie Y.K. A peripheral mononeuropathy in rat that 
produces disorders of pain sensation like those seen in man. 
Pain. 1988; 33: 87-107. 
21.  Storkson R.V., Kjorsvik A., Tjolsen A., Hole K. Lumbar cathete-
rization of the spinal subarachnoid space in the rat. J. Neurosci 
Methods. 1996; 65: 167-72. 
22. Milligan E.D., Hinde J.L., Mehmert K.K., Maier S.F., Watkins 
L.R. A method for increasing the viability of the external por-
tion of lumbar catheters placed in the spinal subarachnoid 
space of rats. J. Neurosci Methods. 1999; 90: 81-6. 
23. Hargreaves K., Dubner R., Brown F., Flores C., Joris J. A new 
and sensitive method for measuring thermal nociception in 
cutaneous hyperalgesia. Pain. 1988; 32: 77–9. 
24. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., Yaksh T.L. 
Quantitative assessment of tactile allodynia in the rat paw. J. 
Neurosci. Methods. 1994; 53: 55-63. 
25. Milligan E.D., O'Connor K.A., Nguyen K.T., Armstrong C.B., 
Twining C., Gaykema R.P., Holguin A., Martin D., Maier S.F., 
Watkins L.R. Intrathecal HIV-1 envelope glycoprotein gp120 
induces enhanced pain states mediated by spinal cord proin-
flammatory cytokines. J. Neurosci. 2001; 21: 2808-19. 
26.  An G., Lin T.N., Liu J.S., Xue J.J., He Y.Y., Hsu C.Y. Expression 
of c-fos and c-jun family genes after focal cerebral ischemia. 
Ann. Neurol. 1993; 33: 457-64. 
27.  Bettoni I., Comelli F., Rossini C., Granucci F., Giagnoni G., Peri 
F., Costa B. Glial TLR4 receptor as new target to treat neuro-
pathic pain: efficacy of a new receptor antagonist in a model of 
peripheral nerve injury in mice. Glia. 2008; 56: 1312-9. 
28.  Jordan J.M., Woods M.E., Olano J., Walker D.H. The absence of 
Toll-like receptor 4 signaling in C3H/HeJ mice predisposes 
them to overwhelming rickettsial infection and decreased pro-
tective Th1 responses. Infect Immun. 2008; 76: 3717-24. 
29.  Achenbach T., Brunner B., Heermeier K. Oligonucleotide-based 
knockdown technologies: antisense versus RNA interference. 
Chembiochem. 2003; 4: 928-35. 
30. Uprichard SL. The therapeutic potential of RNA interference. 
FEBS Letters. 2005; 579: 5996-6007. 
31. Dorn G., Patel S., Wotherspoon G., Hemmings-Mieszczak M., 
Barclay J., Natt F.J., Martin P., Bevan S., Fox A., Ganju P., Wi-
shart W., Hall J. siRNA relieves chronic neuropathic pain. 
Nucleic. Acids. Res. 2004; 32: e49. 
32. Tan P.H., Yang L.C., Shih H.C., Lan K.C., Cheng J.T. Gene 
knockdown with intrathecal siRNA of NMDA receptor NR2B 
subunit reduces formalin-induced nociception in the rat. Gene. 
Ther. 2005; 12: 59-66. 
33.  Luo M.C., Zhang D.Q., Ma S.W., Huang Y.Y., Shuster S.J., Por-
reca F., Lai J. An efficient intrathecal delivery of small interfer-
ing RNA to the spinal cord and peripheral neurons. Mol. Pain. 
2005; 1: 29-36. 
34.  Knight SW, Bass BL. A role for the RNase III enzyme DCR - 1 in 
RNA interference and germ line development in Caenorhabdi-
tis elegans. Science. 2001; 293: 2269 - 71. 
35.  Elbashir S., Harborth J., Weber K. Analysis of gene function in 
somatic mammalian cells using small interfering RNAs. Me-
thods. 2002; 26: 199-213. 
36.  Denkers E.Y., Butcher B.A., Del Rio L., Kim L. Manipulation of 
mitogen-activated protein kinase/nuclear fac-
tor-kappaB-signaling cascades during intracellular Toxoplasma 
gondii infection. Immunol Rev. 2004; 201: 191-205. 
37. Maulik D., Ashraf Q.M., Mishra O.P., Delivoria-Papadopoulos 
M. Activation of p38 mitogen-activated protein kinase (p38 
MAPK), extracellular signal-regulated kinase (ERK) and c-jun 
N-terminal kinase (JNK) during hypoxia in cerebral cortical 
nuclei of guinea pig fetus at term: role of nitric oxide. Neurosci 
Lett. 2008; 439: 94-9. 
38.  Ji R.R., Gereau R.W., Malcangio M., Strichartz G.R. MAP kinase 
and pain. Brain Res. Rev. 2009; 60: 135-48. 
39. Gao Y.J., Ji R.R. Activation of JNK pathway in persistent pain. 
Neurosci. Lett. 2008; 437: 180-3. 
40.  Crown E.D., Gwak Y.S., Ye Z., Johnson K.M., Hulsebosch C.E. 
Activation of p38 MAP kinase is involved in central neuro-
pathic pain following spinal cord injury. Exp. Neurol. 2008; 213: 
257-67. 
41.  Gu Y.W., Su D.S., Tian J., Wang X.R. Attenuating phosphoryla-
tion of p38 MAPK in the activated microglia: a new mechanism 
for intrathecal lidocaine reversing tactile allodynia following 
chronic constriction injury in rats. Neurosci. Lett. 2008; 431: 
129-34. 
42. Li M.M., Yu Y.Q., Fu H., Xie F., Xu L.X., Chen J. Extracellular 
signal-regulated kinases mediate melittin-induced hypersensi-
tivity of spinal neurons to chemical and thermal but not me-
chanical stimuli. Brain. Res. Bull. 2008; 77: 227-32. 
43.  Liu S, Yang J, Wang L, Jiang M, Qiu Q, Ma Z, Liu L, Li C, Ren C, 
Zhou J, Li W. Tibia Tumors -Induced Cancer Pain Involves 
Spinal p38 Mitogen-Activated Protein Kinase Activation via 
TLR4-Dependent Mechanisms. Brain Res. 2010; [Epub ahead of 
print] 
44. Sun T, Cui CB, Luo JG, Zhang L, Fu ZJ, Song WG. Effect of 
electroacupuncture on the expression of spinal glial fibrillary 
acidic protein, tumor necrosis factor-alpha and interleu-
kin-1beta in chronic neuropathic pain rats. Zhen Ci Yan Jiu. 
2010; 35(1): 12-6. 
45. Sahbaie P, Shi X, Guo TZ, Qiao Y, Yeomans DC, Kingery WS, 
Clark JD. Role of substance P signaling in enhanced nociceptive 
sensitization and local cytokine production after incision. Pain. 
2009; 145(3): 341-9. 
46. Jancálek R, Dubový P, Svízenská I, Klusáková I. Bilateral 
changes of TNF-alpha and IL-10 protein in the lumbar and cer-
vical dorsal root ganglia following a unilateral chronic con-
striction injury of the sciatic nerve. J Neuroinflammation. 2010; 
10: 7-11. 